by American College of Physicians Long-term treatment with immediate-release isradipine does not seem to slow the clinical progression of early-stage Parkinson’s disease. Findings from a multicenter, randomized, parallel-group, double-blind, placebo-controlled trial are published in Annals of Internal Medicine. Despite multiple prior studies, there are no proven strategies for slowing the progression of Parkinson’s disease. Isradipine,...
